A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure
Authors:
- Signe GlargaardSGSigne Glargaard
- Jakob Hartvig ThomsenJTJakob Hartvig Thomsen
- Christian TuxenCTChristian Tuxen
- Matias Greve LindholmMLMatias Greve Lindholm
- Christian Axel BangCBChristian Axel Bang
- Morten SchouMSMorten Schou
- Kasper IversenKIKasper Iversen
- Rasmus Vedby RasmussenRRRasmus Vedby Rasmussen
- Brian Bridal LøgstrupBLBrian Bridal Løgstrup
- Søren VraaSVSøren Vraa
- Nis StrideNSNis Stride
- Ekim SevenESEkim Seven
Open Access
- 22 April 2025
- journal article
- Published by Wolters Kluwer Health in Circulation
- Vol. 151 (16) , 1150-1161
Abstract
BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion–Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion. METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle. RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group ( P =0.42). The mortality rate was 13% in both groups, with no difference in survival probability ( P =0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7], P =0.69). Major complications occurred in 1% of thoracenteses performed during the study period. CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05017753.Keywords
This publication has 38 references indexed in Scilit:
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart FailureJACC, 2022
- Effect of a Strategy of Comprehensive Vasodilation Versus Usual Care on Health-Related Quality of Life Among Patients with Acute Heart FailureESC Heart Failure, 2021
- Outcomes of Thoracentesis for Acute Heart Failure in HospitalsThe American Journal of Cardiology, 2020
- The Use of Diuretics in Heart Failure with Congestion — A Position Statement from the Heart Failure Association of the European Society of CardiologyEuropean Journal of Heart Failure, 2019
- Confidence intervals of the Mann‐Whitney parameter that are compatible with the Wilcoxon‐Mann‐Whitney testStatistics in Medicine, 2018
- Pleural effusions in acute decompensated heart failure: Prevalence and prognostic implicationsEuropean Journal of Internal Medicine, 2018
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsJACC, 2018
- Nonmalignant Pleural EffusionsChest, 2017
- Does This Patient Have an Exudative Pleural Effusion?JAMA, 2014
- Long-term survival after hospitalization for acute heart failure — Differences in prognosis of acutely decompensated chronic and new-onset acute heart failureInternational Journal of Cardiology, 2013